Cisapride
|
|
|
| |
| cis-4-amino-5-chloro-N-[1- [3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]- 2-methoxybenzamide | |
| CAS number 81098-60-4 | ATC code A03FA02 |
| Chemical formula | C23H29ClFN3O4 |
| Molecular weight | 465.9 |
| Bioavailability | ~100% |
| Metabolism | hepatic, intestinal |
| Elimination half life | 10 hours |
| Excretion | renal, biliary |
| Pregnancy category | B1 (Australia) |
| Legal status | Schedule 4 (Australia) |
| Delivery | tablets, suspension |
Cisapride is a parasympathomimetic which acts as a serotonin 5-HT4 agonist. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. It is sold under the trade names Prepulsid (Janssen-Ortho) and Propulsid (in the U.S.).
Clinical uses
Cisapride increases muscle tone in the esophageal sphincter in people with gastroesophageal reflux disease. It also increases gastric emptying in people with diabetic gastroparesis. It has been used to treat bowel constipation.
In many countries it has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.
Sources
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4